PRVB - Provention Bio GAAP EPS of -$0.35 beats by $0.11 revenue of $0.58M misses by $0.12M
Provention Bio press release (NASDAQ:PRVB): Q1 GAAP EPS of -$0.35 beats by $0.11. Revenue of $0.58M misses by $0.12M. As of March 31, 2022, Provention had cash, cash equivalents and marketable securities of $113.4 million.
For further details see:
Provention Bio GAAP EPS of -$0.35 beats by $0.11, revenue of $0.58M misses by $0.12M